Mark Gergen, Poseida CEO
Poseida lines up another allogeneic CAR-T partner, allying with Astellas on solid tumors
Astellas will buy about 8.8% of Poseida Therapeutics for $25 million, and match that with a one-time payment for right of first refusal to license …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
